How Do Oxidized Phospholipids Inhibit LPS Signaling?
Nigel Mackman I n 1981, Henriksen and coworkers 1 reported that oxidized LDL (oxLDL) induces cholesterol accumulation in macrophages. This observation formed the basis of the hypothesis that oxidation of LDL might be an important step in the atherogenesis process. Many subsequent studies support the oxidative modification hypothesis of atherogenesis. [2] [3] [4] However, oxidation of LDL is a complex process. Both the protein and the lipid molecules of LDL can be oxidatively modified resulting in a variety of biologically active molecules. The primary targets of oxidation are the esterified polyunsaturated fatty acids in the phospholipid shell that surrounds the insoluble neutral lipids of the lipoprotein core ( Figure 1A ). Importantly, atherosclerotic lesions contain antigens recognized by antibodies generated against oxLDL, demonstrating the presence of oxLDL in vivo. [5] [6] [7] 
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OxLDL has both stimulatory and inhibitory effects on gene expression in vascular cells, such as monocytes/macrophages, endothelial cells, and smooth muscle cells. Different lipid oxidation products, such as oxidized phospholipids, oxidized cholesterol esters, and isoprostanes, were found to activate endothelial cells. 8 -11 In addition, lysophosphatidic acid induced TF expression in smooth muscle cells. 12 Other studies by Marathe and coworkers 13 demonstrated that one of the phospholipids oxidation products of oxidized LDL was a platelet-activating factor (PAF)-like molecule that activated the PAF receptor on platelets and leukocytes. Cushing et al 14 and Rajavashisth et al 15 showed that minimally oxidized LDL (mmLDL) induced the expression of chemokines and cytokines by endothelial cells ( Figure 1A ). Another study showed that mmLDL induced tissue factor (TF) expression in endothelial cells. 16 The effects of mmLDL were found to be mediated by a G protein-coupled receptor via a cAMPdependent pathway, [17] [18] [19] although the specific receptor has not yet been identified. Interestingly, the effects of oxidized phospholipids can be blocked by PAF receptor antagonists, 20, 21 suggesting that the receptor may be related to the PAF receptor.
Watson and coworkers 9 isolated and partially characterized some bioactive oxidized phospholipids in mmLDL. Oxidized 1-palmitoyl-2-arachnidonoyl-sn-glycero-3-phosphorylcholine (ox-PAPC), which includes 1-palmitoyl-2(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine (POVPC) and 1-palmitoyl-2-glutaroyl-snglycero-3-phosphorylcholine (PGPC), was present in mmLDL and activated endothelial cells. 19, 22 oxPAPC also was shown to activate the transcription factors PPAR␣, Egr-1, and NFAT but not NF-B, and induce the expression of the pro-atherogenic genes MCP-1, IL-8, and TF in endothelial cells 23 ( Figure 1A ). oxPAPC induction of the IL-8 promoter was mediated by cis-acting DNA elements that were distinct from those required for induction by TNF␣, indicating that these agonists activated different transcription factors. 24 Lipopolysaccharide (LPS), also known as endotoxin, is the principal component of the outer membrane of Gramnegative bacteria. 25 In humans, the presence of LPS in the blood is detected by serum-binding proteins and cell surface receptors on monocytes and endothelial cells 26 ( Figure 1B ). Exposure of these cells to LPS induces the expression of a variety of pro-inflammatory genes that combat the bacterial infection. However, an over-reaction to LPS can lead to septic shock and death. 27 Many of the steps in the interaction of LPS with monocytes and endothelial cells have been elucidated in the past 10 years. 26, 28 The serum binding protein, LPS binding protein (LBP), delivers LPS to the phosphatidylinositol glycan-linked cell surface protein, CD14 ( Figure 1B) . Subsequently, the LPS-CD14 complex interacts with toll-like receptor 4 (TLR4) and its accessory protein, MD2, or is incorporated into the plasma membrane ( Figure 1B) . 29, 28 Other studies indicate that the LPS signaling complex is assembled within lipid rafts and caveolae. 30, 31 The intracellular adaptor proteins MyD88 and Mal are recruited to the Toll/IL-1 receptor (TIR) cytoplasmic domain of TLR4, which leads to the activation of various intracellular signaling pathways, such as the inhibitor of kappa B kinase (IKK) and mitogen activated kinase pathways. 32 Transcription factors, such as NF-B, AP-1, and Egr-1, have been shown to mediate the LPS induction of pro-inflammatory genes, which include TNF␣, IL-8, MCP-1, and TF. 33 LPS and oxPAPC activate some of the same intracellular signaling pathways and genes. For instance, LPS and ox-PAPC both induce MCP-1 and IL-8 expression in endothelial cells. However, LPS and oxPAPC also exhibit differences in the pattern of gene expression. For example, E-selectin is induced only by LPS and heme oxygenase 1 is induced only by oxPAPC. 19, 23 A key difference between LPS and oxPAPC is that LPS is a potent activator of NF-B, whereas oxPAPC does not activate NF-B. Importantly, several studies have shown that oxLDL and oxidized phospholipids inhibit LPS induction of NF-B and gene expression in monocytes/macrophages and endothelial cells. 19,34 -37 OxLDL inhibited LPS activation of NF-B and induction of IL-12 and Cox-2 expression in macrophages, and lysophosphatidylcholine inhibited LPS induction of TF in monocytes. 19 cells. 35 However, the mechanism(s) by which oxidized phospholipids inhibited LPS induction of gene expression was not elucidated. In this issue, Walton and coworkers 38 report their studies of the mechanism by which oxPAPC inhibits LPS induction of IL-8 and MCP-1 in endothelial cells and macrophages. Cell fractionation and immunofluorescence were used to analyze caveolae and assembly of the LPS signaling complex ( Figure  2A ). They showed that oxPAPC disrupted caveolae and inhibited the assembly of the LPS signaling complex in endothelial cells. OxPAPC also inhibited TLR4-and TLR2-mediated induction of IL-8 and MCP-1 expression in human macrophages, presumably due to inhibition of the assembly of the LPS signaling complex in lipid rafts. These results suggest a common mechanism of oxPAPC inhibition of LPS signaling in endothelial cells and macrophages. OxPAPC inhibition of LPS induction of IL-8 and MCP-1 expression in endothelial cells and macrophages was selective because oxPAPC did not affect TNF␣ induction of these chemokines. These authors did not find evidence that oxPAPC inhibited the binding of biotinylated LPS to the cells.
In contrast to the studies by Walton and colleagues, 38 Bochkov and coworkers 39 proposed a different inhibitory mechanism to explain how oxPAPC inhibits LPS signaling in human endothelial cells. They showed that oxPAPC inhibited LPS signaling by blocking the binding of LPS to LBP and CD14 ( Figure 2B ). In addition, oxPAPC protected mice treated with a lethal dose of LPS. 39 Binding of oxPAPC to CD14 appears to form an inactive complex because it does not engage TLR4 and activate NF-B. The reason for the different results generated by these groups is unclear. Both studies used oxPAPC, but used different types of endothelial cells. Walton and coworkers 38 used human aortic endothelial cells (HAECs), which express CD14 on their surfaces in a manner similar to monocytes. Bochkov and coworkers 39 used human umbilical vein endothelial cells (HUVECs), which utilize soluble CD14 for LPS activation. 40 OxPAPC may bind to soluble CD14 more efficiently than membrane bound CD14, making HUVECs more susceptible than HAECs to inhibition by this pathway.
Recently, Miller and coworkers 41 reported that mmLDL binds to CD14 via a binding site that is distinct from the LPS binding site. Furthermore, they showed that TLR4 was required for mmLDL-induced spreading of human macrophages. This suggests an additional mechanism that may contribute to the inhibitory effects of mmLDL on LPS signaling. If the TLR4/MD2 complex binds to an mmLDL-CD14 complex, it would reduce the amount of TLR4/MD2 that is available to participate in the LPS signaling complex ( Figure 2C ). Importantly, an mmLDL-CD14-TLR4 complex would be expected to activate NF-B, but this has not been shown and the TLR4 ligand within mmLDL has not been defined.
In summary, two studies have reported distinct inhibitory mechanisms to explain how oxPAPC inhibits LPS signaling in human endothelial cells and macrophages. The differences may be due to the use of different cell types. It is intriguing that structural similarities between LPS and oxPAPC may permit their recognition by the pattern recognition receptor, CD14. In addition, LPS and mmLDL both bind to TLR4. LPS binding to CD14 induces an acute inflammatory response that results in septic shock. In contrast, mmLDL and oxPAPC induces chronic inflammation that contributes to atherosclerosis. Further studies are required to elucidate the role of CD14 and TLR4 in atherosclerosis. Early reports suggest a link between TLR4 and atherosclerosis 42, 43 consistent with the hypothesis that innate immunity may contribute to atherogenesis. 44 
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